NGM Biopharmaceuticals
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $122.0Mattributed |
|---|---|
| Latest round | series-a, $122.0M, 2024-07-01attributed |
| Founded | 2008 |
| Headquarters | South San Francisco CA |
| Industry | biotech|therapeutics|liver |
| Stage | series-a |
| Website | ngmbio.com |
NGM Bio is a clinical-stage biopharmaceutical developing antibody therapeutics targeting GDF15 signalling. It serves patients suffering from hyperemesis gravidarum and cancer cachexia, two conditions with severely limited treatment options. Its lead program NGM120 is the only GDF15/GFRAL antagonist antibody in clinical development across both indications.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-01 | series-a | $122.0M | undisclosed |
Detected tech stack
Vercel, Next.js, React, Webpack
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $122.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $122.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | ngmbio.com, read 2026-05-07 |
| Description | self-reported | ngmbio.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.